Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
Feature|Articles|October 10, 2023

Catalent's Flexible Fill/Finish Capabilities for Drug Products CPHI Barcelona

Catalent provides fill/finish services across a range of product formats from clinical to commercial scale.

From sites in the U.S. and Europe, Catalent provides drug product development and manufacturing services, leveraging proven expertise from pre-clinical to commercial launch and supply of small molecules, biologics, vaccines, and biosimilars. Catalent has extensive experience with drug product process development across a variety of liquid and lyophilized formulations into vials, syringes and cartridges. Our facilities and high-speed filling lines offer aseptic processing that is flexible, fast, and integrated with secondary packaging.

URL: https://biologics.catalent.com/biologics/drug-product

ㅤ

CPHI Barcelona 2023

Booth 3N50

Stop by the Catalent Stand for a Taste of Spain networking reception taking place on Wednesday, October 25, 2023 from 4:30PM-6:30PM.

Related to this article

View more
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
Read more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more